These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28739166)

  • 1. Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.
    Artner C; Holtkamp HU; Hartinger CG; Meier-Menches SM
    J Inorg Biochem; 2017 Dec; 177():322-327. PubMed ID: 28739166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolization of [Ru(eta(6)-C (6)H (5)CF (3))(pta)Cl (2)]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand.
    Egger AE; Hartinger CG; Renfrew AK; Dyson PJ
    J Biol Inorg Chem; 2010 Aug; 15(6):919-27. PubMed ID: 20364440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.
    Jarosz M; Matczuk M; Pawlak K; Timerbaev AR
    Anal Chim Acta; 2014 Dec; 851():72-7. PubMed ID: 25440667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties.
    Battistin F; Scaletti F; Balducci G; Pillozzi S; Arcangeli A; Messori L; Alessio E
    J Inorg Biochem; 2016 Jul; 160():180-8. PubMed ID: 26920229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action.
    Casini A; Karotki A; Gabbiani C; Rugi F; Vašák M; Messori L; Dyson PJ
    Metallomics; 2009 Sep; 1(5):434-41. PubMed ID: 21305148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metallomics for drug development: a further insight into intracellular activation chemistry of a ruthenium(III)-based anticancer drug gained using a multidimensional analytical approach.
    Matczuk M; Prządka M; Aleksenko SS; Czarnocki Z; Pawlak K; Timerbaev AR; Jarosz M
    Metallomics; 2014 Jan; 6(1):147-53. PubMed ID: 24247321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.
    Scolaro C; Chaplin AB; Hartinger CG; Bergamo A; Cocchietto M; Keppler BK; Sava G; Dyson PJ
    Dalton Trans; 2007 Nov; (43):5065-72. PubMed ID: 17992291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competition between glutathione and DNA oligonucleotides for ruthenium(II) arene anticancer complexes.
    Wang F; Xu J; Wu K; Weidt SK; Mackay CL; Langridge-Smith PR; Sadler PJ
    Dalton Trans; 2013 Mar; 42(9):3188-95. PubMed ID: 23076358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of interstrand migration of organoruthenium anticancer complexes within a DNA duplex.
    Wu K; Luo Q; Hu W; Li X; Wang F; Xiong S; Sadler PJ
    Metallomics; 2012 Feb; 4(2):139-48. PubMed ID: 22262368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Not All Binding Sites Are Equal: Site Determination and Folding State Analysis of Gas-Phase Protein-Metallodrug Adducts.
    Eade L; Sullivan MP; Allison TM; Goldstone DC; Hartinger CG
    Chemistry; 2024 May; 30(28):e202400268. PubMed ID: 38472116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro ruthenation of human breast cancer suppressor gene 1 (BRCA1) by the antimetastasis compound RAPTA-C and its analogue CarboRAPTA-C.
    Ratanaphan A; Temboot P; Dyson PJ
    Chem Biodivers; 2010 May; 7(5):1290-302. PubMed ID: 20491084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards Light-Activated Ruthenium-Arene (RAPTA-Type) Prodrug Candidates.
    Renfrew AK; Karges J; Scopelliti R; Bobbink FD; Nowak-Sliwinska P; Gasser G; Dyson PJ
    Chembiochem; 2019 Nov; 20(22):2876-2882. PubMed ID: 31102568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds.
    Dorcier A; Hartinger CG; Scopelliti R; Fish RH; Keppler BK; Dyson PJ
    J Inorg Biochem; 2008; 102(5-6):1066-76. PubMed ID: 18086499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity.
    Hartinger CG; Casini A; Duhot C; Tsybin YO; Messori L; Dyson PJ
    J Inorg Biochem; 2008 Dec; 102(12):2136-41. PubMed ID: 18834634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
    Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
    Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands.
    Kilpin KJ; Cammack SM; Clavel CM; Dyson PJ
    Dalton Trans; 2013 Feb; 42(6):2008-14. PubMed ID: 23187957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Competitive binding sites of a ruthenium arene anticancer complex on oligonucleotides studied by mass spectrometry: ladder-sequencing versus top-down.
    Wu K; Hu W; Luo Q; Li X; Xiong S; Sadler PJ; Wang F
    J Am Soc Mass Spectrom; 2013 Mar; 24(3):410-20. PubMed ID: 23404464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound.
    Casini A; Gabbiani C; Michelucci E; Pieraccini G; Moneti G; Dyson PJ; Messori L
    J Biol Inorg Chem; 2009 Jun; 14(5):761-70. PubMed ID: 19288144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
    Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
    Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of ICP-MS, capillary electrophoresis, and their hyphenation for probing Ru(III) metallodrug-DNA interactions.
    Foteeva LS; Matczuk M; Pawlak K; Aleksenko SS; Nosenko SV; Karandashev VK; Jarosz M; Timerbaev AR
    Anal Bioanal Chem; 2017 Mar; 409(9):2421-2427. PubMed ID: 28116493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.